C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

por Temesgen, Zelalem, Kelley, Colleen F, Cerasoli, Frank, Kilcoyne, Adrian, Chappell, Dale, Durrant, Cameron, Ahmed, Omar, Chappell, Gabrielle, Catterson, Victoria, Polk, Christopher, Badley, Andrew, Marconi, Vincent C
Publicado 2023

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL

por TEMESGEN, ZELALEM, BURGER, CHARLES, BAKER, JASON, POLK, CHRISTOPHER, LIBERTIN, CLAUDIA, KELLEY, COLLEEN, MARCONI, VINCENT, ORENSTEIN, ROBERT, CATTERSON, VICTORIA, ARONSTEIN, WILLIAM, DURRANT, CAMERON, CHAPPELL, DALE, CHAPPELL, GABRIELLE, AHMED, OMAR, BADLEY, ANDREW
Publicado 2021

40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial

por Temesgem, Zelalem, Burger, Charles, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent, Orenstein, Robert, Catterson, Victoria, Aronstein, William, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew
Publicado 2021

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

por Temesgen, Zelalem, Burger, Charles D, Baker, Jason, Polk, Christopher, Libertin, Claudia R, Kelley, Colleen F, Marconi, Vincent C, Orenstein, Robert, Catterson, Victoria M, Aronstein, William S, Durrant, Cameron, Chappell, Dale, Ahmed, Omar, Chappell, Gabrielle, Badley, Andrew D
Publicado 2022